Preoperative empagliflozin and ventricular remodeling after coronary artery bypass grafting in type 2 diabetes: a prespecified analysis of the POST-CABGDM randomized trial
Abstract
Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are associated with adverse ventricular remodeling. Coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) may further contribute to myocardial injury through inflammatory and ischemia–reperfusion mechanisms. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardioprotective effects, including reduction in left ventricular mass, but their impact in the perioperative setting of cardiac surgery remains unclear.
This study is a prespecified secondary analysis of the open-label randomized POST-CABGDM trial (NCT04523064). Patients with T2DM and multivessel CAD undergoing CABG with CPB were randomized to receive empagliflozin 25 mg once daily or standard antidiabetic therapy. SGLT2i were discontinued 3 days before surgery and were not protocol-mandated postoperatively. Transthoracic echocardiography was performed preoperatively and at 1–6 months postoperatively. The primary endpoint was the change in left ventricular mass index (ΔLVMI). Secondary endpoints included changes in left ventricular ejection fraction (ΔLVEF) and ventricular dimensions.
A total of 118 patients were included (53 in the intervention group and 65 in the control group). Baseline characteristics were well balanced. No significant difference was observed in ΔLVMI between groups (− 1.39 ± 18.7 vs. −4.55 ± 16.8 g/m²;
p
= 0.337), and this finding remained unchanged after adjustment for baseline LVMI. Similarly,…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 118 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.